Unforeseen complications of pembrolizumab in breast reconstruction post-mastectomy
  • Murad Aldarayseh
    Internal Medicine Department, RWJ Barnabas Health/Trinitas Regional Medical Center, Elizabeth, USA
  • Sohail Singh Sodhi
    Internal Medicine Department, RWJ Barnabas Health/Trinitas Regional Medical Center, Elizabeth, USA
  • Gamal Musleh
    Internal Medicine Department, RWJ Barnabas Health/Trinitas Regional Medical Center, Elizabeth, USA
  • Dyuti Kumar
    St George’s University School of Medicine, Grenada, West Indies
  • Michelle Cholankeril
    Internal Medicine Department, RWJ Barnabas Health/Trinitas Regional Medical Center, Elizabeth, USA

Keywords

Pembrolizumab, breast reconstruction, breast cancer

Abstract

A 53-year-old post-menopausal Indian female presented with invasive ductal carcinoma, treated with neoadjuvant chemotherapy and pembrolizumab due to a PD-L1 combined positive score of 5. Following a right mastectomy and axillary dissection, she received a breast expander and AlloDerm™ graft. After resuming pembrolizumab and paclitaxel postoperatively, she developed severe breast redness and high-grade fever, necessitating expander removal due to suspected pembrolizumab-induced complications. This case underscores the unique and severe adverse effects of pembrolizumab on breast reconstruction, highlighting the need for careful monitoring and management in patients undergoing similar treatments.

VIEW THE ENTIRE ARTICLE

References

  • Poole RM. Pembrolizumab: first global approval. Drugs 2014;74:1973–1981.
  • Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020;382:810–821.
  • Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016;2:1346–1353.
  • Ni D, AlZahrani F, Smylie M. AIHA and pancytopenia as complications of pembrolizumab therapy for metastatic melanoma: a case report. Case Rep Oncol 2019;12:456–465.
  • Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother 2017;66:25–32.
  • Lipson EJ, Naqvi FF, Loss MJ, Schollenberger MD, Pardoll DM, Moore J Jr, et al. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection. Am J Transplant 2020;20:2264–2268.
  • Cui X, Yan C, Xu Y, Li D, Guo M, Sun L, Zhu Z. Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: a safety analysis from a literature review and a pharmacovigilance system. Cancer Med 2023;12:5181–5194.
  • Aguirre LE, Guzman ME, Lopes G, Hurley J. Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue. Oncologist 2019; 24:394–401.
  • Berry T, Brooks S, Sydow N, Djohan R, Nutter B, Lyons J, et al. Complication rates of radiation on tissue expander and autologous tissue breast reconstruction. Ann Surg Oncol 2010;17(Suppl. 3):202–210.
  • Views: 163
    HTML downloads: 10
    PDF downloads: 87


    Published: 2024-07-01
    Issue: 2024: Vol 11 No 7 (view)


    How to cite:
    1.
    Aldarayseh M, Sodhi SS, Musleh G, Kumar D, Cholankeril M. Unforeseen complications of pembrolizumab in breast reconstruction post-mastectomy. EJCRIM 2024;11 doi:10.12890/2024_004675.

    Most read articles by the same author(s)